What Is Slowing Industrialization Of Korean Digital Healthcare?
Data Use Ambiguity, Regulatory Hurdles
At a recent policy forum in Korea to discuss regulatory improvements, participants talked about the factors keeping the digital healthcare industry from taking off, despite ongoing efforts.
You may also be interested in...
Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.